oral sel. PDE2A phosphodiesterase inhibitor

for cognition, target engagement in brain

from HTS, SBDD, and FEP claculations

J. Med. Chem., Oct. 26, 2020

Janssen Pharmaceutica NV, Beerse, BE

“compound 46” (Janssen oral selective brain-penetrant PDE2A phosphodiesterase inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks